{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T20:38:29Z","timestamp":1776371909811,"version":"3.51.2"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosurg Rev"],"DOI":"10.1007\/s10143-024-02889-w","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T03:43:47Z","timestamp":1727408627000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Application of bevacizumab in the management of meningiomas: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8801-1158","authenticated-orcid":false,"given":"Bardia","family":"Hajikarimloo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6183-084X","authenticated-orcid":false,"given":"Arman","family":"Hasanzade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1233-4940","authenticated-orcid":false,"given":"Mohammadamin","family":"Sabbagh Alvani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7600-6925","authenticated-orcid":false,"given":"Mohammad Amin","family":"Habibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"2889_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.wneu.2022.04.048","volume":"163","author":"VM Lu","year":"2022","unstructured":"Lu VM et al (2022) The emerging relevance of H3K27 trimethylation loss in Meningioma: a systematic review of recurrence and overall survival with Meta-analysis. World Neurosurg 163:87\u201395e1","journal-title":"World Neurosurg"},{"key":"2889_CR2","doi-asserted-by":"publisher","unstructured":"Bai X, Liu X, Wen J (2022) Efficacy of bevacizumab in high-grade meningiomas: a retrospective clinical study. Neuropsychiatr Dis Treat 18:1619\u20131627. https:\/\/doi.org\/10.2147\/NDT.S368740","DOI":"10.2147\/NDT.S368740"},{"key":"2889_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11060-021-03741-7","volume":"153","author":"T Le Van","year":"2021","unstructured":"Le Van T et al (2021) Multimodal management of surgery-and radiation-refractory meningiomas: an analysis of the French national tumor board meeting on meningiomas cohort. J Neurooncol 153:55\u201364","journal-title":"J Neurooncol"},{"issue":"1","key":"2889_CR4","doi-asserted-by":"publisher","first-page":"vdac123","DOI":"10.1093\/noajnl\/vdac123","volume":"4","author":"P Kumthekar","year":"2022","unstructured":"Kumthekar P et al (2022) A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma. Neuro-Oncology Adv 4(1):vdac123","journal-title":"Neuro-Oncology Adv"},{"issue":"2","key":"2889_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11060-016-2172-3","volume":"129","author":"KC Shih","year":"2016","unstructured":"Shih KC et al (2016) A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma. J Neurooncol 129(2):281\u2013288","journal-title":"J Neurooncol"},{"key":"2889_CR6","doi-asserted-by":"publisher","unstructured":"Hess K et al (2020) Occurrence of Fibrotic Tumor vessels in Grade I meningiomas is strongly Associated with Vessel Density, expression of VEGF, PlGF, IGFBP-3 and Tumor Recurrence. Cancers 12. https:\/\/doi.org\/10.3390\/cancers12103075","DOI":"10.3390\/cancers12103075"},{"key":"2889_CR7","doi-asserted-by":"publisher","unstructured":"Shao Z, Liu L, Zheng Y, Tu S, Pan Y, Yan S, Wei Q, Shao A, Zhang J. Molecular mechanism and approach in progression of meningioma. Front Oncol 2020;10:538845. https:\/\/doi.org\/10.3389\/fonc.2020.538845","DOI":"10.3389\/fonc.2020.538845"},{"key":"2889_CR8","doi-asserted-by":"crossref","unstructured":"Habibi MA et al (2024) The safety and efficacy of bevacizumab in treatment of recurrent low-grade glioma: a systematic review and meta-analysis. European Journal of Clinical Pharmacology","DOI":"10.1007\/s00228-024-03695-5"},{"issue":"1","key":"2889_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s10143-024-02585-9","volume":"47","author":"MA Habibi","year":"2024","unstructured":"Habibi MA et al (2024) Stereotactic radiosurgery versus combined stereotactic radiosurgery and bevacizumab for recurrent glioblastoma; a systematic review and meta-analysis of survival. Neurosurg Rev 47(1):323","journal-title":"Neurosurg Rev"},{"issue":"1","key":"2889_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11060-012-0861-0","volume":"109","author":"E Lou","year":"2012","unstructured":"Lou E et al (2012) Bevacizumab therapy for adults with recurrent\/progressive meningioma: a retrospective series. J Neurooncol 109(1):63\u201370","journal-title":"J Neurooncol"},{"issue":"9","key":"2889_CR11","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.rec.2021.07.010","volume":"74","author":"MJ Page","year":"2021","unstructured":"Page MJ et al (2021) Declaraci\u00f3n PRISMA 2020: una gu\u00eda actualizada para la publicaci\u00f3n de revisiones sistem\u00e1ticas. Revista Espa\u00f1ola De Cardiolog\u00eda (English Edition) 74(9):790\u2013799","journal-title":"Revista Espa\u00f1ola De Cardiolog\u00eda (English Edition)"},{"key":"2889_CR12","doi-asserted-by":"crossref","unstructured":"Aromataris E, Porritt LC, Pilla K, Jordan B Z, (eds) (2024) JBI Manual for evidence synthesis. JBI","DOI":"10.46658\/JBIMES-24-01"},{"key":"2889_CR13","doi-asserted-by":"crossref","unstructured":"Deeks JJ et al (2019) Analysing data and undertaking meta-analyses, in Cochrane Handbook for Systematic Reviews of Interventions. pp. 241\u2013284","DOI":"10.1002\/9781119536604.ch10"},{"key":"2889_CR14","doi-asserted-by":"publisher","unstructured":"Franke AJ, Skelton WP IV, Woody LE, Bregy A, Shah AH, Vakharia K, Komotar RJ. Role of bevacizumab for treatment-refractory meningiomas: a systematic analysis and literature review. Surg Neurol Int 2018;9:133. https:\/\/doi.org\/10.4103\/sni.sni_264_17","DOI":"10.4103\/sni.sni_264_17"},{"issue":"1","key":"2889_CR15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11060-012-0886-4","volume":"109","author":"L Nayak","year":"2012","unstructured":"Nayak L et al (2012) Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol 109(1):187\u2013193","journal-title":"J Neurooncol"},{"issue":"2","key":"2889_CR16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3171\/jns.2002.97.2.0341","volume":"97","author":"WP Mason","year":"2002","unstructured":"Mason WP et al (2002) Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningiomas. J Neurosurg 97(2):341\u2013346","journal-title":"J Neurosurg"},{"issue":"4","key":"2889_CR17","doi-asserted-by":"publisher","first-page":"E11","DOI":"10.3171\/FOC-07\/10\/E11","volume":"23","author":"HB Newton","year":"2007","unstructured":"Newton HB (2007) Hydroxyurea chemotherapy in the treatment of meningiomas. Neurosurgical Focus FOC 23(4):E11","journal-title":"Neurosurgical Focus FOC"},{"issue":"2","key":"2889_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s11060-009-9948-7","volume":"96","author":"AD Norden","year":"2010","unstructured":"Norden AD et al (2010) Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol 96(2):211\u2013217","journal-title":"J Neurooncol"},{"issue":"1","key":"2889_CR19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11060-014-1358-9","volume":"117","author":"JJ Raizer","year":"2014","unstructured":"Raizer JJ et al (2014) A phase II trial of PTK787\/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas. J Neurooncol 117(1):93\u2013101","journal-title":"J Neurooncol"},{"key":"2889_CR20","doi-asserted-by":"publisher","unstructured":"Wang EJ, Haddad AF, Young JS, Morshed RA, Wu JPH, Salha DM, Butowski N, Aghi MK. Recent advances in the molecular prognostication of meningiomas. Front Oncol 2023;12:910199. https:\/\/doi.org\/10.3389\/fonc.2022.910199","DOI":"10.3389\/fonc.2022.910199"},{"issue":"1","key":"2889_CR21","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13014-015-0446-0","volume":"10","author":"M Furuse","year":"2015","unstructured":"Furuse M et al (2015) Intratumoral and peritumoral post-irradiation changes, but not viable tumor tissue, may respond to bevacizumab in previously irradiated meningiomas. Radiat Oncol 10(1):156","journal-title":"Radiat Oncol"},{"issue":"2","key":"2889_CR22","first-page":"234","volume":"21","author":"RY Huang","year":"2019","unstructured":"Huang RY et al (2019) Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progression. Neurooncology 21(2):234\u2013241","journal-title":"Neurooncology"},{"issue":"03","key":"2889_CR23","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1055\/s-0033-1338262","volume":"74","author":"AH Hawasli","year":"2013","unstructured":"Hawasli AH et al (2013) Antiangiogenic agents for nonmalignant brain tumors. J Neurol Surg B Skull Base 74(03):136\u2013141","journal-title":"J Neurol Surg B Skull Base"},{"issue":"11","key":"2889_CR24","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1007\/s00701-022-05348-x","volume":"164","author":"AY Alexander","year":"2022","unstructured":"Alexander AY et al (2022) The role of bevacizumab for treatment-refractory intracranial meningiomas: a single institution\u2019s experience and a systematic review of the literature. Acta Neurochir 164(11):3011\u20133023","journal-title":"Acta Neurochir"},{"issue":"11","key":"2889_CR25","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3109\/00207454.2015.1092443","volume":"126","author":"MC Alanin","year":"2016","unstructured":"Alanin MC et al (2016) Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 \u2013 a retrospective case series. Int J Neurosci 126(11):1002\u20131006","journal-title":"Int J Neurosci"},{"issue":"3","key":"2889_CR26","doi-asserted-by":"publisher","first-page":"e59941","DOI":"10.1371\/journal.pone.0059941","volume":"8","author":"FP Nunes","year":"2013","unstructured":"Nunes FP et al (2013) Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients. PLoS ONE 8(3):e59941","journal-title":"PLoS ONE"},{"issue":"4","key":"2889_CR27","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1056\/NEJMoa0902579","volume":"361","author":"SR Plotkin","year":"2009","unstructured":"Plotkin SR et al (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361(4):358\u2013367","journal-title":"N Engl J Med"},{"key":"2889_CR28","doi-asserted-by":"crossref","unstructured":"Alanin MC et al (2015) The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2, vol 272. European Archives of Oto-Rhino-Laryngology, pp 3627\u20133633. 12","DOI":"10.1007\/s00405-014-3398-3"}],"container-title":["Neurosurgical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-024-02889-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10143-024-02889-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-024-02889-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T10:37:06Z","timestamp":1741084626000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10143-024-02889-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2889"],"URL":"https:\/\/doi.org\/10.1007\/s10143-024-02889-w","relation":{},"ISSN":["1437-2320"],"issn-type":[{"value":"1437-2320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"6 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is deemed exempt from receiving ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"692"}}